Evidence map›Paper›PMID 36481664›Full record

ArticleScientific reports2022

Dysregulated thrombospondin 1 and miRNA-29a-3p in severe COVID-19.

In Soo Kim, Sung-Gwon Lee, Seul Gi Shin, Hyeongseok Jeong, Kyung Mok Sohn, Ki-Sun Park, Prashanta Silwal, Shinhye Cheon, Jungok Kim, Sungmin Kym and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Emerging functions of thrombospondin-1 in immunity.Seminars in cell & developmental biology · 2024
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

In Soo Kim *Department of Medical Science, Chungnam National University School of Medicine, Daejeon, Korea.
Sung-Gwon Lee *School of Biological Sciences and Technology, Chonnam National University, Gwangju, Korea.
Seul Gi Shin *Department of Microbiology, Chungnam National University School of Medicine, Daejeon, Korea.
Hyeongseok Jeong *Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
Kyung Mok SohnDivision of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
Ki-Sun ParkKM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, Korea.
Prashanta SilwalDepartment of Microbiology, Chungnam National University School of Medicine, Daejeon, Korea.
Shinhye CheonDivision of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
Jungok KimDivision of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
Sungmin KymDivision of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
Yeon-Sook KimDivision of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. alice@cnuh.co.kr.
Eun-Kyeong JoDepartment of Medical Science, Chungnam National University School of Medicine, Daejeon, Korea. hayoungj@cnu.ac.kr.ORCID 0000-0001-7191-0587
Chungoo ParkSchool of Biological Sciences and Technology, Chonnam National University, Gwangju, Korea. chungoo@jnu.ac.kr.
Chungnam National University · KRChonnam National University · KRKorea Institute of Oriental Medicine · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although nearly a fifth of symptomatic COVID-19 patients suffers from severe pulmonary inflammation, the mechanism of developing severe illness is not yet fully understood. To identify significantly altered genes in severe COVID-19, we generated messenger RNA and micro-RNA profiling data of peripheral blood mononuclear cells (PBMCs) from five COVID-19 patients (2 severe and 3 mild patients) and three healthy controls (HC). For further evaluation, two publicly available RNA-Seq datasets (GSE157103 and GSE152418) and one single-cell RNA-Seq dataset (GSE174072) were employed. Based on RNA-Seq datasets, thrombospondin 1 (THBS1) and interleukin-17 receptor A (IL17RA) were significantly upregulated in severe COVID-19 patients' blood. From single-cell RNA-sequencing data, IL17RA level is increased in monocytes and neutrophils, whereas THBS1 level is mainly increased in the platelets. Moreover, we identified three differentially expressed microRNAs in severe COVID-19 using micro-RNA sequencings. Intriguingly, hsa-miR-29a-3p significantly downregulated in severe COVID-19 was predicted to bind the 3'-untranslated regions of both IL17RA and THBS1 mRNAs. Further validation analysis of our cohort (8 HC, 7 severe and 8 mild patients) showed that THBS1, but not IL17RA, was significantly upregulated, whereas hsa-miR-29a-3p was downregulated, in PBMCs from severe patients. These findings strongly suggest that dysregulated expression of THBS1, IL17RA, and hsa-miR-29a-3p involves severe COVID-19.

Indexed as

COVID-19MicroRNAsHumansLeukocytes, MononuclearThrombospondin 1MicroRNAsThrombospondin 1

Identifiers

PMID36481664
PMCPMC9732043
OpenAlexW4311577980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.